Publication | Closed Access

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

HepatologyMedicinePathologyLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaAdvanced Hepatocellular Carcinoma